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OBJECTIVE — Although A1C is now recommended to diagnose diabetes, its test perfor-
mancefordiagnosisandprognosisisuncertain.Ourobjectivewastoassessthetestperformance
of A1C against single and repeat glucose measurements for diagnosis of prevalent diabetes and
for prediction of incident diabetes.
RESEARCH DESIGN AND METHODS — We conducted population-based analyses of
12,485 participants in the Atherosclerosis Risk in Communities (ARIC) study and a subpopu-
lation of 691 participants in the Third National Health and Nutrition Examination Survey
(NHANES III) with repeat test results.
RESULTS — Against a single fasting glucose 126 mg/dl, the sensitivity and speciﬁcity of
A1C 6.5% for detection of prevalent diabetes were 47 and 98%, respectively (area under the
curve 0.892). Against repeated fasting glucose (3 years apart) 126 mg/dl, sensitivity improved
to 67% and speciﬁcity remained high (97%) (AUC 0.936). Similar results were obtained in
NHANES III against repeated fasting glucose 2 weeks apart. The accuracy of A1C was consistent
across age, BMI, and race groups. For individuals with fasting glucose 126 mg/dl and A1C
6.5% at baseline, the 10-year risk of diagnosed diabetes was 88% compared with 55% among
those individuals with fasting glucose 126 mg/dl and A1C 5.7–6.5%.
CONCLUSIONS — A1C performs well as a diagnostic tool when diabetes deﬁnitions that
most closely resemble those used in clinical practice are used as the “gold standard.” The high
risk of diabetes among individuals with both elevated fasting glucose and A1C suggests a dual
role for fasting glucose and A1C for prediction of diabetes.
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A
lthough A1C is now recommended
for the diagnosis of diabetes (1,2),
its precise test performance is un-
certain. The lack of a single, clear “gold
standard” poses a challenge for determin-
ing the performance of A1C. Previous di-
agnostic studies of A1C have relied
exclusively on a single elevated fasting or
2-h glucose values as gold standards (3–
5). However, because glucose determina-
tions are inherently more variable than
A1C (6), these convenient gold standards
are likely to reduce the apparent accuracy
of A1C as a diagnostic test. A stronger
goldstandardwouldrelyonrepeatedglu-
cosedeterminationsondifferentdays(2),
i.e., the recommended approach to diag-
nosis of diabetes in clinical practice. Al-
ternatively, A1C and fasting glucose can
be compared head-to-head against the
subsequent development of clinically di-
agnosed diabetes as the gold standard.
We hypothesized that 1) A1C would per-
form well as a diagnostic and prognostic
testfordiabetesacrossitsfullrangeandat
the American Diabetes Association–
recommended threshold of 6.5% and 2)
that its performance would be best when
judged against stronger, most clinically
relevant gold standards.
RESEARCH DESIGN AND
METHODS
Atherosclerosis risk in communities
study
The Atherosclerosis Risk in Communities
(ARIC) study is a community-based co-
hortstudyof15,792blackorwhiteadults
aged 45–64 years at baseline sampled
from four U.S. communities. The ﬁrst
clinical examinations (visit 1) took place
during 1987–1989, with three follow-up
visits approximately every 3 years. Infor-
mation on diabetes status including self-
reported physician diagnosis, diabetes
medication use, and fasting glucose mea-
surements was obtained from all partici-
pants at each clinical examination (7).
Visit 2 (1990–1992), attended by 14,348
participants, was the only visit for which
stored whole blood samples were avail-
able for measurement of A1C and is the
baseline for the present study. We ex-
cluded participants who identiﬁed race/
ethnicity as other than white or black,
who had a self-reported physician diag-
nosis of diabetes or diabetes medication
use (visit 1 or visit 2), who were nonfast-
ing, or who were missing variables of in-
terest; thus, the ﬁnal sample size for our
main analyses was 12,485 individuals.
Second examination of the third
national health and nutrition
examination survey
TheSecondExaminationoftheThirdNa-
tional Health and Nutrition Examination
Survey(NHANESIIISecondExam)wasa
substudy of NHANES III, conducted in
1988–1994 (8). A nonrandom sample of
2,596 participants in the original
NHANES III was selected for participa-
tion in this substudy; these data comprise
one of the largest available databases of
short-term repeat laboratory and physical
examination measurements in humans
(6,9,10). We excluded NHANES III Sec-
ond Exam participants who were aged
18 years (n  387), who were fasting
8h( n  1,411), who reported a prior
physician diagnosis of diabetes (n  53),
or who were missing glucose or A1C val-
ues (n  54). After these exclusions, 691
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glucose tolerance tests (OGTTs) were
only performed on individuals who were
aged 40–74 years and who had morning
examinations; all analyses of 2-h glucose
measurementswerelimitedtothesmaller
sample of individuals with valid OGTT
data (n  317).
Measurement of glucose and A1C
In the ARIC study, serum glucose was
measured from blood collected at each
visit using the hexokinase method. We
thawed and assayed frozen whole blood
samples collected at ARIC study visit 2
(1990–1992) for measurement of A1C
using high-performance liquid chroma-
tography (Tosoh 2.2 Plus in 2003–2004
andTosohG7in2007–2008,TosohCor-
poration, Tokyo, Japan) (standardized to
the Diabetes Control and Complications
Trial [DCCT] assay) (11). Because A1C
data are only available at visit 2 in the
ARIC study, this was used as the baseline
examination in the present study.
In addition to plasma glucose mea-
surements, the NHANES III examination
included a 2-h 75-g OGTT in adults aged
40–75 years. A1C measurements were
obtained using the Diamat high-
performance liquid chromatography as-
say (Bio-Rad Laboratories) (standardized
to the DCCT assay). Because variant he-
moglobins can interfere with A1C mea-
surement by the Diamat assay, samples
with evidence of interference were reana-
lyzed by afﬁnity chromatography. The
NHANES III repeat examinations were
conducted approximately 2 weeks after
theﬁrstexaminationbytrainedpersonnel
following the same standardized proto-
cols(6).Detailedinformationondatacol-
lection and laboratory procedures in
NHANES III are described elsewhere
(12,13).
Prevalent undiagnosed diabetes
In the ARIC and NHANES III studies, we
usedtherepeatglucosevaluesavailableto
comparedifferentdeﬁnitionsofprevalent
undiagnosed diabetes (Table 2). In the
ARIC study, we generated two principle
deﬁnitions of prevalent diabetes (deﬁni-
tion1:asinglefastingglucosevalue126
mg/dl at baseline [visit 2]; and deﬁnition
2: fasting glucose values 126 mg/dl at
two separate examinations). In the ARIC
study, the two fasting glucose measure-
ments took place at the clinical examina-
tions that were 3 years apart. In the
NHANESIIIsubpopulation,thetwoclin-
ical examinations took place 2 weeks
apart (mean 17 days). In the NHANES III
subpopulation, we also examined indi-
viduals with undiagnosed diabetes de-
ﬁned by single and repeat 2-h glucose
values 200 mg/dl.
Incident diabetes in the ARIC study
On-going longitudinal follow-up of ARIC
study participants also provided us the
opportunity to assess the performance of
baseline A1C for classiﬁcation of incident
diabetes. We used two deﬁnitions of inci-
dent diabetes: a visit-based deﬁnition
(deﬁnitionA)andaninterview-baseddef-
inition(deﬁnitionB).FordeﬁnitionA,we
used a standard time-to-diabetes deﬁni-
tionbasedonglucosemeasurements,self-
reported diagnosis, or medication use for
a maximum of 6 years of follow-up (14).
FordeﬁnitionB,weusedself-reportedin-
formation on diabetes diagnosis and
medication use during the visits and sub-
sequent annual telephone calls for a max-
imum of 15 years of follow-up (15).
Statistical analyses
We examined population characteristics
by diagnostic categories of A1C (6.5%
and6.5%)amongindividualswithouta
history of diagnosed diabetes in the ARIC
and NHANES III populations. We calcu-
lated the sensitivity, speciﬁcity, and posi-
tive and negative likelihood ratios at all
cutoffs of A1C for each deﬁnition of prev-
alent and incident diabetes. We calcu-
lated the area under the receiver operator
characteristic (ROC) curve (AUC) for
A1C overall and by subgroups of the
population in the ARIC study only (the
samplesizefortheNHANESIIIsubpopu-
lation was insufﬁcient for subgroup anal-
yses): age (60 or 60 years), race/
ethnicity (white or African American),
and BMI categories (25, 25–30, or
30 kg/m
2). We also conducted sensitiv-
ity analyses in individuals with anemia.
We used data from the ARIC study to es-
timate the subsequent risk of diabetes
during follow-up (15). Using the Kaplan-
Meier method, we estimated the 10-year
cumulative incidence of diagnosed diabe-
tes according to clinical categories of
baseline fasting glucose and A1C.
RESULTS— The characteristics of the
study populations by A1C 6.5% and
6.5% are shown in Table 1. Among
NHANES III participants with A1C
6.5% at the baseline examination, 80%
(61–92%) also had A1C 6.5% at the
second examination 17 days later.
Among participants with fasting glucose
126 mg/dl at baseline, 70% (50–86%)
had fasting glucose 126 mg/dl at the
second examination. In the ARIC study,
60%(57–64%)ofparticipantswithafast-
ing glucose 126 mg/dl at the baseline
examination also had a fasting glucose
126 mg/dl at the 3-year follow-up visit.
Repeat A1C measurements were not
available in the ARIC study.
The AUCs for A1C for the identiﬁca-
tionofdiabetesusingmultipledeﬁnitions
are shown in Table 2. In the ARIC study,
the highest AUC was for diabetes deﬁned
by two fasting glucose measurements
126 mg/dl, 3 years apart (deﬁnition 2):
AUC 0.936 (95% CI 0.920–0.952). The
accuracyofA1Cwasconsistentacrossage
and race groups, but there was a signiﬁ-
cantdifferenceintheaccuracyacrossBMI
categories (supplementary Table, avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc10-1235/DC1). For deﬁnition 1, the
accuracy of A1C was lower among nor-
mal-weight individuals compared with
overweight and obese individuals. How-
ever, for deﬁnition 2, A1C demonstrated
high and consistent accuracy across all
BMI groups. The AUCs were also high in
NHANES for both deﬁnitions (Table 2).
The AUC for A1C for a single fasting glu-
cose at baseline as the gold standard in
NHANES III (deﬁnition 1) was (0.938
[95% CI 0.881–0.995]), but the sample
size was small (n  29 cases of diabetes),
with corresponding imprecision re-
ﬂected in the wide CIs. Two-hour glu-
cose measurements were also available
in NHANES III, and analyses using single
and repeated 2-h glucose measurements
demonstrated similarly high AUCs. For
instance, the AUC for A1C was 0.959
(0.899–1.00) for diabetes deﬁned as a
fasting glucose 126 and 2-h glucose
200 mg/dl at the baseline examination.
TheAUCsforfastingglucose126mg/dl
and 2-h glucose 200 mg/dl at both the
baseline and follow-up examination 17
days later were identical (0.959 [0.885–
1.000]),but,again,thenumberofcasesof
diabetes in this study population was
small (n  14).
The ROC curves for A1C in the ARIC
study comparing deﬁnitions 1 and 2 are
shown in Fig. 1. The sensitivity and spec-
iﬁcity of A1C 6.5% for identifying cases
of diabetes by deﬁnition 1 (single fasting
glucose 126 mg/dl) were 47 and 98%,
respectively. For deﬁnition 2 (fasting glu-
cose 126 mg/dl at two time points, 3
years apart), the sensitivity was 67% and
the speciﬁcity was 97%. Detailed infor-
Selvin and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 85mation on the sensitivity, speciﬁcity, and
positive and negative likelihood ratios of
all A1C cutoffs for each deﬁnition of dia-
betes in ARIC and NHANES III are pre-
sented in the supplementary Table. The
prevalence of anemia (hemoglobin 13
g/dl in men and 12 g/dl in women [16])
was 9.9% in the ARIC population. In
analyses among individuals with anemia,
the overall performance (AUC), sensitiv-
ity, and speciﬁcity of A1C were similar
(data not shown).
Follow-up data available in the ARIC
study allowed us to examine the perfor-
mance of A1C for prediction of subsequent
diabetes (Table 2). The AUC for the visit-
detected cases of diabetes during 6 years of
follow-up (deﬁnition A) was 0.827 (0.813–
0.840). The AUC for diagnosed (interview-
based) diabetes risk during a median of 14
years of follow-up (deﬁnition B) was 0.733
(0.722–0.745). However, the AUC for in-
terview-based diagnosed cases during the
ﬁrst6yearsoffollow-uponlywassimilarto
that for the visit-detected cases: 0.826
(0.800–0.851).
The 10-year risk of diagnosed diabe-
tes was 12% (11–13%) and the 15-year
risk was 25% (24–26%) in the ARIC
study. The 10-year risks of diagnosed di-
abetes stratiﬁed by categories of baseline
andA1Candfastingglucoseareshownin
Fig. 2.
CONCLUSIONS — The accuracy of
A1C for diagnosis of prevalent diabetes
was high for all reference deﬁnitions and
robust across subpopulations (all AUCs
0.80). However, the sensitivity and
speciﬁcityofA1C6.5%toidentifycases
of undiagnosed diabetes varied, depend-
ing on the deﬁnition of undiagnosed dia-
betes used as the gold standard. Use of
repeat glucose tests to deﬁne diabetes
substantially reduced the proportion of
Table 1—Participant characteristics by A1C category among persons without a history of diagnosed diabetes: ARIC and NHANES III study
populations
ARIC study population (n  12,485) NHANES III subpopulation (n  691)
A1C 6.5% A1C 6.5% A1C 6.5% A1C 6.5%
n 11,925 (95.5) 460 (4.49) 660 (95.5) 31 (4.5)
Age (years) 56.8  5.7 57.8  5.7 46.7  17.5 57.8  14.3
Male sex (%) 44.5 41.6 49.1 58.1
African American (%) 20.9 50.4 28.2 61.3
Less than high school education (%) 19.4 34.9 34.5 58.1
BMI (kg/m
2) 27.5  5.1 32.4  6.2 27.7  6.3 30.4  4.9
Obese (%) 25.2 60.8 28.5 54.8
Current smoker (%) 22.2 23.5 27.7 16.1
Hypertension (%) 32.4 57.2 27.4 58.1
Total cholesterol (mg/dl) 209.2  38.5 218.3  41.9 206.1  42.1 215.4  40.5
HDL cholesterol (mg/dl) 50.5  16.8 43.1  14.0 50.5  14.7 46.1  15.7
Triglycerides (mg/dl) 110.0 (80.0, 155.0) 140.0 (101.0, 199.0) 113.0 (82.0, 167.5) 181.0 (141.0, 229.0)
Family history of diabetes (%) 22.1 33.9 22.4 19.4
Data are n (%), means  SD, median (25th percentile, 75th percentile), or proportions (%).
Table 2—AUC (95%CI) for A1C for the detection of glucose-based deﬁnitions of diabetes: ARIC study and NHANES III Second Exam
participants, adults without a history of diagnosed diabetes at baseline
Diabetes deﬁnition description
ARIC study (n  12, 485) NHANES III (n  691)
n (cases) AUC (95% CI) n (cases) AUC (95% CI)
Prevalent diabetes
Deﬁnition 1 Fasting glucose 126 mg/dl at the baseline
examination
840 0.892 (0.878–0.905) 29 0.938 (0.881–0.995)
Deﬁnition 2 Fasting glucose 126 mg/dl at two separate
visits*
234 0.936 (0.920–0.952) 21 0.921 (0.843–0.999)
Incident diabetes
Deﬁnition A† Visit-detected incident diabetes (fasting
glucose 126, medication use, or self-
report) during 6 years of follow-up
1,308 0.827 (0.813–0.840) — —
Deﬁnition B Interview-detected diagnosed diabetes
during 15 years of follow-up
2,614 0.733 (0.722–0.745) — —
Years 0–6 456 0.826 (0.800–0.851) — —
Years 6–12 1,376 0.669 (0.646–0.691) — —
Years 12–15 782 0.628 (0.607–0.648) — —
*In the ARIC study, the second examination took place 3 years after the baseline examination. In the NHANES III study population, the second examination took
place 17 days after the baseline examination. †n  12,060 after exclusion of individuals with fasting glucose 126 mg/dl at baseline or missing glucose
measurements during follow-up.
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ularly individuals with fasting glucose
(126 mg/dl) and A1C (6.5%). In this
study, a value of A1C 6.5% strongly
predicted a subsequent diagnosis of dia-
betes, even among individuals classiﬁed
ashavingundiagnoseddiabetesbyfasting
glucose. We observed that those with
high A1C but without elevated fasting
glucose had a lower incidence of diag-
nosed diabetes than those meeting both
the glucose and A1C criteria. Such results
suggest a dual role for A1C and glucose
for the prediction of diabetes.
New guidelines for the use of A1C for
the diagnosis of diabetes recommend that
an elevated A1C or fasting glucose or
OGTT results be conﬁrmed on a second
occasion or that the diagnosis be con-
ﬁrmed by a different test on the same oc-
casion. Analyses of short-term (6) and
long-term reliability (17) have demon-
strated that A1C is signiﬁcantly less vari-
able than fasting glucose or 2-h glucose.
Our data suggest an A1C 6.5% con-
ﬁrmed by a fasting glucose 126 mg/dl
on the same occasion has a high positive
predictive value (88%) for 10-year diabe-
tes risk. We observed a substantial risk of
diagnosed diabetes at high levels of A1C
regardless of the baseline fasting glucose
level, consistent with previous analyses of
these data (15). However, the observed
diabetesriskamongindividualsindiscor-
dant A1C and fasting glucose risk catego-
ries suggests the utility of using both A1C
and fasting glucose to reduce misclassiﬁ-
cation and accurately identify individuals
at risk of future diabetes.
An A1C cut point of 6.5% is highly
speciﬁc but has low sensitivity for the
identiﬁcation of prevalent undiagnosed
diabetes by these deﬁnitions. The low
sensitivity of A1C does not necessarily
mean that A1C has poor test perfor-
mance; it may be that A1C is more appro-
priately distinguishing those individuals
atriskforsubsequentcomplications.Rec-
ommendations for use of A1C for diagno-
sis, monitoring glycemic control, and
guiding therapy in diabetes are largely
based on the association of A1C with
long-term microvascular outcomes (2).
Epidemiological studies have also dem-
onstrated associations among A1C and
risk of diabetes, cardiovascular disease,
and all-cause mortality in nondiabetic in-
dividuals (15), with substantial increases
in risk observed at A1C values 6.0%.
Prospective epidemiological data demon-
strate that A1C is a stronger predictor of
vascular complications than fasting glu-
cose (15).
As has been shown in previous stud-
ies (18,19), blacks were substantially
more likely to have elevated A1C values
than whites. Nonetheless, we did not ob-
serve substantial racial differences in the
overall performance of A1C for the iden-
tiﬁcation or prediction of diabetes.
This study highlights a weakness in
the literature related to diabetes diagno-
sis: the lack of conﬁrmatory glucose test-
ing to replicate the typical clinical
scenario in which multiple tests are con-
ducted before a diagnosis is made. In
studieswithnoconﬁrmatorytesting,A1C
will seem to miss a proportion of fasting
glucose-deﬁned cases of diabetes. This is
partly a function of the short-term vari-
ability in fasting glucose. When repeat
testing is used, this discordance is re-
duced. We have shown previously that
A1C has substantially lower within-
person variability compared with fasting
and 2-h glucose (6). Whereas repeating
fasting glucose tests can substantially
reducemisclassiﬁcation,thehighreliabil-
ity of A1C suggests that a single measure-
ment is sufﬁcient for diagnostic
classiﬁcation unless laboratory error or
interference is suspected.
For diabetes and other asymptomatic
conditions that are clinically deﬁned,
diagnostic testing studies should use
multiple reference standards, ideally em-
phasizingthosethatmostcloselyreplicate
the clinical setting. Previous studies have
highlighted the low sensitivity of A1C for
detectingdiabetesdeﬁnedbyasinglefast-
ing or 2-h glucose measurement
(3,5,20,21). Our data demonstrated im-
proved performance of A1C compared
with stronger gold standards that relied
on repeated glucose determinations on
different days.
A number of limitations of this study
should be considered. This study was not
a traditional diagnostic testing study, and
we did not conduct a head-to-head com-
parison of the accuracy of glucose com-
paredwithA1C;forthis,athirdreference
standard would be needed. The small
number of cases of diabetes by any deﬁ-
nition among participants in the
NHANES III subsample resulted in im-
precision of our estimates and prevented
further subgroup analyses in this popula-
tion.Wealsodidnothaveinformationon
2-h glucose at the time of A1C measure-
ment in the ARIC study. Nonetheless, the
ARIC study is one of the largest U.S. co-
Figure1—AreaundertheROCcurveforA1C(%)forthedetectionofglucose-baseddeﬁnitionsof
diabetes,theARICstudy(n12,485),adultswithoutahistoryofdiagnoseddiabetes.——,ROC
curve for deﬁnition 1 (fasting glucose 126 mg/dl at baseline), AUC 0.892; – – –, ROC curve for
deﬁnition 2 (fasting glucose 126 mg/dl on two separate occasions, 3 years apart), AUC 0.936.
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the development of diabetes. The addi-
tionalanalysesofNHANESdemonstrated
consistency across populations and al-
lowed us to examine deﬁnitions of diabe-
tes based on short-term repeat glucose
measurements (weeks apart).
In summary, we found that A1C per-
forms best when more stringent glucose
criteria are used to deﬁne diabetes (i.e.,
fasting glucose 126 mg/dl on two
separate occasions), similar to clinical
practice. Our data support current rec-
ommendations for use of A1C in the di-
agnosis of diabetes and demonstrate that
an A1C cutoff of 6.5% is highly speciﬁc
and may be reasonably sensitive in the
context of evidence linking A1C to risk of
long-term microvascular and macrovas-
cularoutcomesinnondiabeticadults.We
also found that A1C and fasting glucose
both strongly predict subsequent risk of
diagnosed diabetes, but the very high risk
observed for individuals with both ele-
vated fasting glucose and A1C suggests a
dual role for fasting glucose and A1C for
prediction of diabetes.
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Figure 2—Ten-year risk of diagnosed diabetes (self-reported diagnosis or medication use) by
baseline fasting glucose and/or A1C categories in the ARIC study, adults without a history of
diagnoseddiabetes(n12,485).A:10-yearriskofdiagnoseddiabetesbyfastingglucosecategory
at baseline. B: 10-year risk of diagnosed diabetes by A1C category at baseline. C: 10-year risk of
diagnosed diabetes by A1C and fasting glucose categories at baseline. I bars are 95% CIs.
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